Key result
Extended release quetiapine use was associated with the development of Neuroleptic Malignant Syndrome in a 50-year-old woman with atypical psychotic disorder.
Why the study?
Does extended release quetiapine cause neuroleptic malignant syndrome in a patient with atypical psychotic disorder?
Case Report (n=1)
Does extended release quetiapine cause neuroleptic malignant syndrome in a patient with atypical psychotic disorder?
Extended-release quetiapine can rarely cause life-threatening neuroleptic malignant syndrome.
Answers are grounded in this paper and cite their sources.
Potential NMS with extended-release quetiapine warrants vigilance; single case leaves open causality and broader risk.
Neuroleptic malignant syndrome (NMS), is a potentially life-threatening condition which is rarely seen during antipsychotic use. Neuroleptic malignant syndrome is characterized by the imbalance of central neurotransmitters, in which a dopaminergic block is developed. Hyperthermia, muscular rigidity, tremor, autonomic dysfunction, an increase in serum creatine phosphokinase levels, leukocytosis, and altered mental status can be seen in this syndrome. In this study, we present a 50 year old woman with NMS that occurred during the use of extended release quetiapine, who had been diagnosed with atypical psychotic disorder for 5 years.
No takes yet. Share an insight, caveat, or question.
Akyüz et al. (2012) conducted a case report in Neuroleptic Malignant Syndrome (n=1). Extended release quetiapine was evaluated on Neuroleptic Malignant Syndrome. Extended release quetiapine use was associated with the development of Neuroleptic Malignant Syndrome in a 50-year-old woman with atypical psychotic disorder.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: